- Home
- HOFT vs BDSX Comparison
HOFT vs BDSX Comparison
Compare HOFT & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOFT
- BDSX
- Stock Information
- Founded
- HOFT 1924
- BDSX 2005
- Country
- HOFT United States
- BDSX United States
- Employees
- HOFT N/A
- BDSX N/A
- Industry
- HOFT Home Furnishings
- BDSX Precision Instruments
- Sector
- HOFT Consumer Discretionary
- BDSX Health Care
- Exchange
- HOFT Nasdaq
- BDSX Nasdaq
- Market Cap
- HOFT 98.1M
- BDSX 115.4M
- IPO Year
- HOFT 1999
- BDSX 2020
- Fundamental
- Price
- HOFT $9.24
- BDSX $0.37
- Analyst Decision
- HOFT
- BDSX Strong Buy
- Analyst Count
- HOFT 0
- BDSX 4
- Target Price
- HOFT N/A
- BDSX $2.83
- AVG Volume (30 Days)
- HOFT 76.5K
- BDSX 638.4K
- Earning Date
- HOFT 06-05-2025
- BDSX 05-13-2025
- Dividend Yield
- HOFT 9.95%
- BDSX N/A
- EPS Growth
- HOFT N/A
- BDSX N/A
- EPS
- HOFT N/A
- BDSX N/A
- Revenue
- HOFT $397,465,000.00
- BDSX $71,323,000.00
- Revenue This Year
- HOFT $5.18
- BDSX $32.90
- Revenue Next Year
- HOFT $6.60
- BDSX $24.65
- P/E Ratio
- HOFT N/A
- BDSX N/A
- Revenue Growth
- HOFT N/A
- BDSX 45.30
- 52 Week Low
- HOFT $7.34
- BDSX $0.45
- 52 Week High
- HOFT $19.79
- BDSX $2.04
- Technical
- Relative Strength Index (RSI)
- HOFT 48.77
- BDSX 29.45
- Support Level
- HOFT $8.46
- BDSX $0.34
- Resistance Level
- HOFT $9.59
- BDSX $0.58
- Average True Range (ATR)
- HOFT 0.49
- BDSX 0.06
- MACD
- HOFT 0.11
- BDSX -0.01
- Stochastic Oscillator
- HOFT 62.40
- BDSX 12.15
About HOFT Hooker Furnishings Corporation
Hooker Furnishings Corp designs, imports, manufactures and market residential household furniture, hospitality and contract furniture, lighting, accessories, and home décor for sale to wholesale and retail merchandisers located principally in North America.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.